학술지 논문

• (2025)  AIM2 drives inflammatory cell death and monkeypox pathogenesis.  CELLULAR & MOLECULAR IMMUNOLOGY.  22,  12
• (2025)  Engineered virus-like particle-assembled Vegfa-targeting Cas9 ribonucleoprotein treatment alleviates neovascularization in wet age-related macular degeneration.  GENOME BIOLOGY.  26,  1
• (2025)  High-efficiency base editing for nuclear and mitochondrial DNA with an optimized DYW-like deaminase.  MOLECULAR THERAPY.  25, 
• (2025)  Four germline POLH variants, including two found in skin tumors, impair DNA polymerase η function and cellular tolerance to UV radiation and cisplatin.  CHEMICO-BIOLOGICAL INTERACTIONS.  416, 
• (2025)  Engineered Sdd7 cytosine base editors with enhanced specificity.  NATURE COMMUNICATIONS.  16,  1
• (2025)  EBP1 potentiates amyloid β pathology by regulating γ-secretase.  NATURE AGING.  5,  3
• (2024)  In vivo adenine base editing rescues adrenoleukodystrophy in a humanized mouse model.  MOLECULAR THERAPY.  32,  7
• (2024)  CRISPR-based editing strategies to rectify EYA1 complex genomic rearrangement linked to haploinsufficiency.  MOLECULAR THERAPY NUCLEIC ACIDS.  35,  2
• (2024)  Precise editing of pathogenic nucleotide repeat expansions in iPSCs using paired prime editor.  NUCLEIC ACIDS RESEARCH.  52,  10
• (2023)  Integrated NLRP3, AIM2, NLRC4, Pyrin inflammasome activation and assembly drive PANoptosis.  CELLULAR & MOLECULAR IMMUNOLOGY.  20,  12
• (2023)  β-arrestin 2 negatively regulates lung cancer progression by inhibiting the TRAF6 signaling axis for NF-κB activation and autophagy induced by TLR3 and TLR4.  CELL DEATH & DISEASE.  14,  7
• (2023)  FFAR2 antagonizes TLR2-and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-kappa B.  CELL AND BIOSCIENCE.  13,  1
• (2023)  DNA double-strand break-free CRISPR interference delays Huntington’s disease progression in mice.  COMMUNICATIONS BIOLOGY.  6,  1
• (2023)  Targeted genomic translocations and inversions generated using a paired prime editing strategy.  MOLECULAR THERAPY.  31,  1
• (2022)  Expanded targeting scope of LbCas12a variants allows editing of multiple oncogenic mutations.  MOLECULAR THERAPY-NUCLEIC ACIDS.  30,  -